BLOOMBERG BNA WEBINAR EVENT: Fraud and Abuse in 2013: Mapping Trends, Strengthening Compliance and Avoiding FCA Actions
Thursday, September 26, 2013
1:00 PM - 2:30 PM ET
Heightened government scrutiny, driven by increasingly strict fraud and abuse provisions, has raised the bar—and the risks—for life sciences companies. In 2012, the Department of Justice recovered $4.96 billion under the False Claims Act, more than $3 billion of that from health care cases. Clearly, health care is under a microscope, and the scrutiny is growing. The Department of Justice is reaching beyond the usual health care statutes to go after life sciences and health care companies in an expanding array of areas—from mail and wire fraud to obstruction—and using more aggressive techniques than ever before, including wire taps and video recordings.
The Department of Health and Human Services (HHS) also has new tools. It now uses predictive modeling to identify fraud and even more demanding corporate integrity agreements. In addition, the Affordable Care Act (ACA) raises penalties up to six times loss or gain for False Claims Act violations in connection with an exchange.
This program helps life sciences and health care companies learn to safely navigate today’s increasingly stringent and complex enforcement environment. It also provides a guide to building and implementing effective compliance programs. Attendees will gain insight into their most critical questions, including:
- What emerging regulations and trends are critical for life sciences and health care companies to be tracking?
- How can institutions and companies strengthen compliance programs to safeguard their organizations including their individual executives?
- What actions should companies take to protect themselves in an increasingly complex enforcement environment?
- How can organizations avoid actions and respond effectively, if they do face an inquiry?
- Learn significant legislative and regulatory developments.
- Understand new enforcement trends for investigating anti-kickback violations, off-label pharmaceutical marketing, and Medicare Part D violations and predictive modeling.
- Discover concrete actions for creating and measuring strong compliance programs—and demonstrating their effectiveness.
- Gain practical recommendations for preparing for and responding to inquiries.
Who would benefit most from attending this program?
The program would be highly valuable for general counsel, officers, managers or directors of compliance, directors and managers of risk services, COOs and CEOs, and outside counsel who practice in the life sciences and/or healthcare spaces.
Program Level: Intermediate.
Credit Available: CLE. For additional information, please see the “CLE Credit” tab.